|1.||Inoue, Hiroshi: 6 articles (11/2015 - 08/2003)|
|2.||Fujiki, Akira: 6 articles (11/2015 - 08/2003)|
|3.||Niwano, Shinichi: 6 articles (01/2011 - 01/2003)|
|4.||Mizumaki, Koichi: 5 articles (11/2015 - 08/2003)|
|5.||Aizawa, Yoshifusa: 5 articles (03/2014 - 01/2007)|
|6.||Izumi, Tohru: 5 articles (01/2011 - 01/2003)|
|7.||Chinushi, Masaomi: 4 articles (03/2014 - 01/2007)|
|8.||Nishida, Kunihiro: 3 articles (11/2015 - 12/2004)|
|9.||Sakabe, Masao: 3 articles (11/2015 - 09/2004)|
|10.||Hosaka, Yukio: 3 articles (03/2014 - 05/2010)|
03/15/1985 - "These studies demonstrate that bepridil results in significant clinical improvement and enhanced LV performance in patients with angina pectoris."
01/01/1985 - "Trials have shown that bepridil is effective in the prophylactic treatment of various forms of angina pectoris and accompanying arrhythmias. "
04/09/1992 - "The 9-year French experience suggests that bepridil is a safe and effective agent for treatment of angina pectoris in properly selected patients."
04/09/1992 - "Comparative efficacy of bepridil versus placebo in angina pectoris: treatment and withdrawal studies."
03/15/1985 - "Long-term efficacy of bepridil in patients with chronic stable angina pectoris: results of a multicenter, placebo-controlled study of extended bepridil use."
12/01/2009 - "Bepridil is highly effective in terminating persistent atrial fibrillation (AF). "
01/01/2011 - "Although bepridil is effective for conversion of long-lasting persistent atrial fibrillation (AF) to sinus rhythm, it sometimes takes a long time to interrupt AF and there is no feasible index to predict its efficacy.In"
11/02/2001 - "Thus, bepridil inhibits hKv1.5 channel current and the inhibitory effect may be useful for the treatment of atrial fibrillation."
12/01/2007 - "As the efficacy of RAS-I in atrial fibrillation is unclear, our study evaluated conversion to and maintenance of sinus rhythm by combination therapy with RAS-I and bepridil in patients in atrial fibrillation. "
06/01/2013 - "Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics."
12/01/1990 - "The results seem to indicate that the efficacy of bepridil in patients with refractory ventricular tachycardia is limited."
11/01/1984 - "To test the efficacy of bepridil as an antidysrhythmic agent, we looked at its effect on the induction of ventricular tachycardia (VT) in dogs, utilizing programmed electrical stimulation (PES). "
04/01/1992 - "The purpose of the study was to evaluate this effect of different doses of intravenous and oral bepridil on the induction of ventricular tachycardia. "
01/01/2011 - "Ventricular tachycardia (VT) induced in the presence of bepridil (1 µM) terminated earlier than in the control. "
04/01/1992 - "Evaluation of bepridil efficacy by electrophysiologic testing in patients with recurrent ventricular tachycardia: comparison of two regimens."
|4.||Torsades de Pointes (Torsade de Pointes)
08/01/2007 - "The addition of bepridil to class I AADs is effective and safe for AF, but careful observation using periodic ECG recordings is essential for avoiding torsades de pointes caused by QT prolongation."
04/09/1992 - "Several comparative clinical trials assessing the safety of bepridil have concluded that the drug may prolong the QT interval in certain patients; however, no occurrence of torsades de pointes was documented in these safety studies. "
06/01/2013 - "Bepridil is used as an antiarrhythmic drug due to its class I, class III, and class IV electrophysiological properties, but it has serious adverse effects such as QT prolongation and torsade de pointes. "
09/01/1994 - "The torsades de pointes with bepridil are serious side-effects, known right from 1982, and for which definite therapeutic recommendations were decreed in 1984 then in 1991. "
09/01/1994 - "[Bepridil and torsades de pointes: are the precautions of use respected?]."
07/01/2007 - "This study tested whether bepridil, a multichannel blocker, would reverse electrical remodeling induced by persistent atrial tachycardia. "
08/01/2010 - "Bepridil (a multiple channel blocker) may markedly prolong the QT interval and induce polymorphic ventricular tachyarrhythmias (VTA). "
01/01/2007 - "Bepridil appears to be useful to suppress drug-refractory ventricular tachyarrhythmia recurrence."
01/01/2007 - "The markers of complete suppression of ventricular tachyarrhythmias during bepridil treatment included a smaller number of VT morphologies, a better NYHA functional class, and a greater drug-induced prolongation of the QT/QTc interval. "
01/01/2007 - "During a mean follow-up of 52+/-44 months, bepridil completely suppressed ventricular tachyarrhythmias in 6 of the 16 patients (38%) and the drug decreased the frequency of ventricular tachyarrhythmia recurrences by >75% in 3 of the other 10 patients. "
|4.||Ion Channels (Ion Channel)
|1.||Electric Countershock (Cardioversion)
|3.||Renal Dialysis (Hemodialysis)
|4.||Vagus Nerve Stimulation